Cargando…

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension

The 34-week double-blind placebo-controlled main phase of REAL 1 (NCT02229851) has been previously presented (Johannsson G et al. 2018.). Now we report the open-label extension of this trial evaluating efficacy and safety of somapacitan in male/female patients aged 23-79 years with AGHD, for an addi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johannsson, Gudmundur, Gordon, Murray, Højby Rasmussen, Michael, Holme Håkonsson, Ida, Sværke, Claus, Tahara, Shigeyuki, Takano, Koji, Biller, Beverly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552458/ http://dx.doi.org/10.1210/js.2019-SAT-LB074

Ejemplares similares

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

THU073 Somapacitan Administered Subcutaneously At 5 mg/1.5 mL Or 10 mg/1.5 mL Strengths Yields Clinically Similar PK And IGF-I Profiles In Healthy Participants
por: Rasmussen, Michael Højby, et al.
Publicado: (2023)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

THU058 Impact Of A Smartphone App On Follow-up Of Adult Growth Hormone Deficiency (AGHD) Patients: Results From The Management Of AGHD (MAGHD) Study
por: De Vincentis, Sara, et al.
Publicado: (2023)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

SUN-LB074 Racial Distribution, Presentation and Outcome in Acromegaly and Cushing's Disease: A Tertiary Referral Center Study in 220 Patients
por: Goswami, Neevedita, et al.
Publicado: (2019)

MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI
por: Martel, Luciana, et al.
Publicado: (2019)

SUN-301 Importance of Sexual Function Assessment in Multidimensional Evaluation of AGHD Patients: Results from the MAGHD Study
por: Monzani, Maria Laura, et al.
Publicado: (2020)

SAT-LB49 Persistent vs Recurrent Cushing’s Disease Diagnosed Four Weeks Post-Partum
por: Nosova, Emily V, et al.
Publicado: (2020)

LBODP074 Autoimmune Hypophysitis: Diagnosis Beyond Imaging
por: Gonzalez, Juanita, et al.
Publicado: (2022)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

MON-330 Cancer Incidence in 1,296 Patients with Acromegaly Is Not Increased: A Nationwide Population-Based Study
por: Esposito, Daniela, et al.
Publicado: (2020)

THU074 Plasma Spexin In Metabolic Syndrome Related To Adult Growth Hormone Deficiency: A Cross-sectional Study
por: Vergani, Edoardo, et al.
Publicado: (2023)

SUN-LB58 Repeated Once-Daily Administration of the Non-Hormonal Neurokinin 1,3 Receptor Antagonist NT-814 Reduces LH, Estradiol and Progesterone in Healthy Women
por: Dhillo, Waljit Singh, et al.
Publicado: (2020)

ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity
por: Klose, Marianne, et al.
Publicado: (2022)

SAT615 Long-term Effects Of Transsphenoidal Surgery On Headache In Patients With Pituitary Tumors - A Prospective Study
por: Hantelius, Victor, et al.
Publicado: (2023)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

MON-LB46 Thyrotropinoma and Pregnancy
por: Namboodiri, Divya, et al.
Publicado: (2020)

SUN-LB070 Who Killed the Pituitary?
por: Chittimoju, Sanjita, et al.
Publicado: (2019)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

MON-LB48 The Genomic Landscape of Sporadic Thyrotrophinomas
por: shen, Angeline, et al.
Publicado: (2020)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

SAT-LB083 Pituitary Apoplexy: What a Headache!
por: Perez Garcia, Yanet, et al.
Publicado: (2019)

SUN-LB069 Pituitary Apoplexy and Pregnancy: Case Report
por: LOTO, MONICA, et al.
Publicado: (2019)

SUN-LB073 Giant Prolactinomas: Recidive (Case Report)
por: Galesanu, Corina
Publicado: (2019)

MON-LB52 Evaluation of Arterial Stiffness in Acromegaly Patients
por: alagüney, sevil, et al.
Publicado: (2020)

SAT-LB46 Depression as an Atypical Presentation of Cushing’s Disease
por: Pahwa, Dhivya, et al.
Publicado: (2020)

OR01-03 DNA Copy Number Profiles In Recurrent And Stable Non-functioning Pituitary Adenomas
por: Johannsson, Gudmundur, et al.
Publicado: (2023)

MON-LB081 Pituitary Adenomas: A Pan-genomic Classification
por: NEOU, Mario, et al.
Publicado: (2019)

SAT-LB47 Tension Pneumothorax Following Cabergoline Initiation for Macroprolactinoma
por: Go, Muriel Tania, et al.
Publicado: (2020)

SUN-LB53 Role of the Glucocorticoid Receptor Phosphorylation in Neural Development
por: Silswal, Neeru, et al.
Publicado: (2020)

SAT-LB48 Novel Genetic Variant of Carney Complex With Acromegaly
por: Cristiano, Elizabeth, et al.
Publicado: (2020)

SAT-LB082 Neurosarcoidosis Presenting as Panhypopituitarism, Diabetes Insipidus and Sellar Mass
por: Saini, Khushpreet Kaur, et al.
Publicado: (2019)

SAT-LB070 Tachykinins Are Essential for the Induction of the Preovulatory LH Surge in Mice
por: Leon, Silvia, et al.
Publicado: (2019)

SUN-LB071 Hodgkin's Lymphoma Presenting with Hypopituitarism: First Reported Case
por: Seymour, Matthew, et al.
Publicado: (2019)

SUN-LB45 Identifying a Role for Lactogenic Hormones in Maternal Motivation
por: Swart, Judith M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sigj2cqr26e8coat91jhe0jd7r